(0.51%) 5 214.08 points
(0.85%) 39 388 points
(0.27%) 16 346 points
(0.59%) $79.73
(1.35%) $2.33
(0.67%) $2 355.90
(0.67%) $28.56
(0.47%) $995.50
(0.09%) $0.928
(-0.08%) $10.86
(0.08%) $0.799
(0.01%) $92.55
-1.17% $ 16.92
@ $16.98
Wydano: 9 geg. 2024 @ 21:23
Zwrot: -0.35%
Poprzedni sygnał: geg. 9 - 20:35
Poprzedni sygnał:
Zwrot: -0.82 %
Live Chart Being Loaded With Signals
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases...
Stats | |
---|---|
Dzisiejszy wolumen | 2.68M |
Średni wolumen | 3.79M |
Kapitalizacja rynkowa | 2.61B |
EPS | $0 ( 2024-05-06 ) |
Następna data zysków | ( $0 ) 2024-07-30 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | 56.40 |
ATR14 | $0.414 (2.45%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-13 | Lonial Sagar | Sell | 5 000 | Common Stock |
2024-03-12 | Charney Laurence N | Sell | 22 000 | Common Stock |
2024-02-14 | Power Sean A | Buy | 0 | |
2024-01-05 | Charney Laurence N | Sell | 17 500 | Common Stock |
2024-01-06 | Weiss Michael S | Buy | 1 001 908 | Common Stock |
INSIDER POWER |
---|
83.32 |
Last 94 transactions |
Buy: 12 977 390 | Sell: 1 920 924 |
Wolumen Korelacja
TG Therapeutics Inc Korelacja
10 Najbardziej pozytywne korelacje | |
---|---|
LWAC | 0.972 |
PUCK | 0.963 |
SCAQ | 0.956 |
NVCN | 0.954 |
ALSA | 0.952 |
KALV | 0.952 |
HERAU | 0.951 |
TWLV | 0.951 |
SY | 0.951 |
NVSA | 0.951 |
10 Najbardziej negatywne korelacje | |
---|---|
AMGN | -0.942 |
NAKD | -0.939 |
STAB | -0.936 |
TUEM | -0.935 |
LGMK | -0.934 |
PROC | -0.933 |
ORPH | -0.932 |
AHPI | -0.931 |
PCSA | -0.928 |
DBGI | -0.92 |
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
TG Therapeutics Inc Korelacja - Waluta/Towar
TG Therapeutics Inc Finanse
Annual | 2023 |
Przychody: | $233.66M |
Zysk brutto: | $219.11M (93.77 %) |
EPS: | $0.0893 |
FY | 2023 |
Przychody: | $233.66M |
Zysk brutto: | $219.11M (93.77 %) |
EPS: | $0.0893 |
FY | 2022 |
Przychody: | $2.79M |
Zysk brutto: | $2.52M (90.48 %) |
EPS: | $-1.510 |
FY | 2021 |
Przychody: | $6.69M |
Zysk brutto: | $5.90M (88.19 %) |
EPS: | $-2.63 |
Financial Reports:
No articles found.
TG Therapeutics Inc
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hodgkin lymphoma, chronic lymphocytic leukemia (CLL), and relapsing forms of multiple sclerosis; and Umbralisib, an oral inhibitor of PI3K-delta and CK1-epsilon for the treatment of CLL, marginal zone lymphoma, and follicular lymphoma. The company also develops Cosibelimab, a human monoclonal antibody of IgG1 subtype that binds to programmed death-ligand 1 (PD-L1) and blocks its interactions with PD-1 and B7.1 receptors; TG-1701 is an orally available and covalently-bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK compared to ibrutinib in in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. In addition, it has various licensed preclinical programs for BET, interleukin-1 receptor associated kinase-4, and GITR; and collaboration agreements with Checkpoint Therapeutics, Inc., Jiangsu Hengrui Medicine Co., Novimmune SA, Ligand Pharmaceuticals Incorporated, and Jubilant Biosys. The company has strategic alliances with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; and Rhizen Pharmaceuticals, S A. TG Therapeutics, Inc. was incorporated in 1993 and is headquartered in New York, New York.
O Sygnały na żywo
Prezentowane na tej stronie sygnały na żywo pomagają określić, kiedy KUPIĆ lub SPRZEDAĆ BRAK DANYCH. Sygnały mogą mieć opóźnienie wynoszące nawet 1 minutę; jak wszystkie sygnały rynkowe, istnieje ryzyko błędu lub pomyłki.
Sygnały transakcyjne na żywo nie są ostateczne i getagraph.com nie ponosi odpowiedzialności za żadne działania podjęte na podstawie tych sygnałów, jak opisano w Warunkach Użytkowania. Sygnały opierają się na szerokim zakresie wskaźników analizy technicznej